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We have developed a mixed ester of hyaluronan with butyric
and retinoic acid (HBR) that acted as a novel cardiogenic/vascu-
logenic agent in human mesenchymal stem cells isolated from
bone marrow, dental pulp, and fetal membranes of term pla-
centa (FMhMSCs). HBR remarkably enhanced vascular endo-
thelial growth factor (VEGF), KDR, and hepatocyte growth fac-
tor (HGF) gene expression and the secretion of the angiogenic,
mitogenic, and antiapoptotic factors VEGF and HGF, priming
stem cell differentiation into endothelial cells. HBR also
increased the transcription of the cardiac lineage-promoting
genes GATA-4 and Nkx-2.5 and the yield of cardiac marker-
expressing cells. These responses were notably more pro-
nounced in FMhMSCs. FMhMSC transplantation into infarcted
rat hearts was associated with increased capillary density, nor-
malization of left ventricular function, and significant decrease
in scar tissue. Transplantation of HBR-preconditioned FMhM-
SCs further enhanced capillary density and the yield of human
vWF-expressing cells, additionally decreasing the infarct size.
Some engrafted, HBR-pretreated FMhMSCs were also positive
for connexin 43 and cardiac troponin I. Thus, the beneficial
effects of HBR-exposed FMhMSCs may be mediated by a large
supply of angiogenic and antiapoptotic factors, and FMhMSC
differentiation into vascular cells. These findings may contrib-
ute to further development in cell therapy of heart failure.
Loss of cardiomyocytes due to myocardial infarction or
hereditary cardiomyopathiesmay represent causative factors in
the progression toward heart failure. In mice, bone marrow-
derived stem cells have been found to enhance functional
recovery in infarcted hearts (1, 2), suggesting that delivery of
these cells may contribute to the regeneration of myocardial
tissue. These observations triggered the launch of numerous
clinical studies to assess the effect of bonemarrow cell injection
into human infarcted hearts. However, the initial observations
and the scientific underpinning of the human trials have been
challenged by a number of studies using mouse bone marrow
hematopoietic cells expressing LacZ or green fluorescent pro-
tein to enable detection in recipient hearts. In these studies little
or no reporter activity could be seen after direct stem cell injec-
tion into the damaged heart or continuous cell transfusion into
the bloodstream of infarcted mice (3, 4). These controversies
prompt further investigations assessing whether cell popula-
tions retaining a therapeutic potential for damaged hearts may
be identified in human bone marrow or alternative sources. In
this regard, human mesenchymal stem cells (hMSCs)2 of bone
marrow (BMhMSCs) display ease of isolation, high expansion
potential, genetic stability, and potential to enhance repair in
many vital tissues (5). BMhMSCs differentiate into cardiomyo-
cytes when cocultured with adult rat ventricular cardiomyo-
cytes (6) or injected into healthy (7) or infarcted (8, 9) animal
hearts, suggesting that BMhMSCs may afford effective cell
therapy of heart failure. Moreover, hMSCs have been found to
express vascular endothelial growth factor (10, 11) and a broad
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spectrum of arteriogenic cytokines promoting in vitro and in
vivo vasculogenesis through paracrine mechanisms (12, 13).
These effects, which are referred to as trophic effects, have been
recently proposed as a major contribution to the therapeutic
potential of MSCs in experimental models of myocardial
infarction (14, 15) and dilated cardiomyopathy (16).
Nevertheless, the use of bone marrow-derived cells is poten-
tially associated with high degree of viral infection and signifi-
cant decline in cell viability anddifferentiationwith age. Besides
bonemarrow, the human dental pulp includes clonogenic, rap-
idly proliferating stem cells (DPhMSCs) sharing an immuno-
phenotype similar to BMhMSCs (17). Fetal membranes may
also represent tissues of particular interest for their role in pre-
venting fetus rejection and their early embryologic origin,
which may entail progenitor potential. Phenotypic and gene
expression studies revealed mesenchymal stem cell-like pro-
files in both amnion and chorion cells of fetal membranes
(FMhMSCs) (18, 19) that were positive for neuronal, pulmo-
nary, adhesion, and migration markers (18). However, albeit
hMSCs may encompass cells committable to cardiovascular
lineages, it is well established that cardiac differentiation is an
extremely low yield process even in embryonic stem (ES) cells.
Hence, affording high-throughput of cardiogenesis in hMSCs
isolated from bone marrow and alternative sources would have
obvious therapeutic potential.
We have recently shown that a mixed ester of hyaluronan with
butyric and retinoic acids (HBR) remarkably increased the yield of
cardiomyocytes derived frommouseES cells (20).Here, we inves-
tigated whether HBR may commit BMhMSCs, DPhMSCs, or
FMhMSCs into cardiovascular lineages and/or enhance their
potential as trophic mediators and whether, in the affirmative,
transplantation of HBR-pretreated hMSCs into infarcted rat
hearts may result in enhanced cardiovascular repair.
MATERIALS ANDMETHODS
Phosphate-buffered saline (PBS), Dulbecco’s modified
Eagle’s medium (DMEM), and fetal bovine serum (FBS) were
purchased from BioWhittaker Cambrex (Walkersville, MD).
Culture flasks were from Falcon BD (Bedford, MA). SH2, SH3,
and SH4 were kindly provided by Dr. Mark Pittenger (Osiris
Therapeutics, Baltimore, MD). Anti-CD29 and anti-CD166
were from Ancell (Bayport, MN). Anti-CD14, anti-CD34, anti-
CD44, and anti-CD45 were from BD Biosciences. The mono-
clonal anti-CD44 antibodyA3D8 and the isotype-matched con-
trol antibody (IgG1) were from Sigma. Primary antibodies
against von Willebrand factor (vWF) and connexin 43 (Cx43)
were from Dako Cytomation (Glostrup, Denmark) and Zymed
Laboratories Inc. (South San Francisco, CA), respectively.
SuperScript II RT and Trizol reagent were from Invitrogen.
Antibodies against human mitochondria were from Chemicon
(Temecula, CA). Goat anti-mouse (TRITC)- and fluorescein
isothiocyanate-conjugated antibodies were from ICN Cappel
(Aurora, OH). SYBRGreen fast start kit (Lightcycler FastStart
DNA MasterPLUS SYBR Green I) was from Roche Diagnostics.
AmpliTaq was fromApplied Biosystems (Foster City, CA). The
MF20 antibody, raised against sarcomeric myosin heavy chain
(MHC), was from Developmental Studies Hybridoma Bank
(The University of Iowa). Monoclonal mouse anticardiac tro-
ponin I (TnI) (clonemAb20) was fromCovance (Berkeley, CA).
Enzyme immunoassays for human vascular endothelial growth
factor (VEGF) and hepatocyte growth factor (HGF) were from
R&D Systems Inc. (Minneapolis, MN). Ficoll-Histopaque, pen-
icillin, streptomycin, amphotericin B,-sarcomeric actinin pri-
mary antibody (clone EA.53), and all the other chemicals were
from Sigma.
Synthesis of HBR—The glycoconjugate HBR is an ester
between the hydroxyl groups of hyaluronan (HA) and the car-
boxyl groups of both butyric acid (BU) and retinoic acid (RA).
The procedure for the synthesis and characterization of HBR
and the related chemical structure are reported in detail else-
where (20). The primary hydroxyl group in position 6 of the
N-acetyl-D-glucosamine residues in the polysaccharide back-
bone is the most reactive toward esterification. The degree of
substitution (DS) was considered as the number of the esteri-
fied OH groups for each repeating unit of hyaluronic acid (Glc-
NAc-GlcUA dimer). All the synthesized HBR exhibited a DS
with BU (DSBU) ranging between 0.05 and 1.5, whereas the DS
with RA (DSRA) was between 0.002 and 0.1. The DSBU/DSRA
ratio was at least 6. The average molecular mass of HBR,
referred to as the average molecular mass of sodium hyaluro-
nate, was determined by high performance size-exclusion chro-
matography and ranged between 10,000 and 30,000 daltons
(20). In theHBRused in the present study, DSBU andDSRAwere
1.44 and 0.032, respectively.
Cell Isolation—According to the policy approved by the local
ethical committee, all tissue samples were obtained after
informed consent.
BMhMSCs—Bonemarrowwas collected fromhealthy volun-
teers in heparinized tubes, diluted 1:3 with PBS, and layered
over a Ficoll-Histopaque gradient (1.077 g/ml). The low density
mononuclear cells were washed twice in PBS, counted, and
plated at 1 106/cm2 in culture flasks inDMEMsupplemented
with 20% heat-inactivated FBS and antibiotics (200 units/ml
penicillin, 100 g/ml streptomycin) and incubated at 37 °C in a
humidified atmosphere with 5% CO2. After 1 week the non-
adherent cells were removed by replacing the medium supple-
mented by 10% FBS. When the cultures were near confluence
(after 2–3 weeks), the cells were detached by treatment with
0.08% trypsin, EDTA (Sigma) and maintained and subcultured
for up to 6–7 passages.
DPhMSCs—Vital human molars were obtained from adult
subjects during a routine dental extraction. The tooth was
immersed in physiological solution containing antibiotics to
eliminate any contamination by the germs present in the oral
cavity. Soon after extraction, the dental crown was fractured in
several parts by means of pliers (bone forceps) under sterile
conditions, and the pulp was uncovered. The tissue fragments
were suspended in DMEM in the presence of 25% FBS, antibi-
otics (200 units/ml penicillin, 100g/ml streptomycin), and 2.5
g/ml amphotericin B. This procedure was followed by incu-
bation at 37 °C in a humidified atmosphere containing 5%CO2,
allowing cells to slip down from the explants and expand up to
confluence. The cell layer was removed by enzymatic digestion
(0.08% trypsin, EDTA) at 37 °C and further expanded inDMEM
containing 10% FBS and antibiotics.
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FMhMSCs—Termplacenta obtained fromcaesarian sections
were rapidly rinsed in PBS containing penicillin and streptomy-
cin and used immediately. Pieces from fetal membranes were
minced and digested for 10 min in DMEM with 0.25% trypsin,
EDTA, 10 units/mlDNase I, and 0.1% collagenase. Tissueswere
pipetted vigorously up and down, avoiding foam for 5 min;
larger pieces of tissue were allowed to settle under gravity for 5
min. Each supernatant was transferred to a fresh tube, neutral-
ized with FBS, then spun at 1500 rpm for 10 min. Each pellet
was resuspended in 5 ml of DMEM containing 20% FBS, 10
units/ml penicillin, and 100 g/ml streptomycin. FMhMSCs
were seeded into 25-cm2 flasks and grown at 37 °C in 5% CO2.
Non-adherent cells were removed after 1 week, and medium
(with 10% FBS) was changed subsequently every 4 days.
Flow Cytometry Analysis—The fibroblast-like cells obtained
frombonemarrow, dental pulp, and fetalmembrane cultures at
the same doubling passage were harvested by treatment with
0.08% trypsin, EDTA and incubated with 1 g/106 cells of flu-
orescein isothiocyanate-conjugated antibodies for 40 min at
4 °C in the dark. The antibodies used were SH2, SH3, SH4,
anti-CD166, anti-CD14, anti-CD34, anti-CD44, and anti-
CD45. After washing, cells were analyzed on a flow cytometer
(FACSCalibur, BD Biosciences) by collecting 10,000 events,
and the data were analyzed using the Cell Quest Software (BD
Biosciences). Flow cytometry analysis was also exploited to
assess the percentage of BMhMSCs,DPhMSCs, and FMhMSCs
expressing -sarcomeric actinin. Cells were harvested by treat-
ment with 0.08% trypsin, EDTA. After a fixation/permeabiliza-
tion step, hMSCs were incubated with a primary antibody
directed against -sarcomeric actinin (1 g/106 cells) for 1 h at
4 °C and with 1 g of fluorescein isothiocyanate-conjugated
secondary antibody for 1 h at 4 °C in the dark. After washing,
cells were analyzed on a flow cytometer (FACSAria, BD Bio-
sciences, San Jose, CA) by collecting 10,000 events, and the data
were analyzed using the FACS Diva software (BD Biosciences).
Gene Expression—Total RNA was isolated by the Trizol rea-
gent (Invitrogen) following the manufacturer’s instructions.
For RT-PCR, cDNAwas synthesized in a 21-l reaction volume
with 2 g of total RNA and SuperScript II RT. To assess
GATA-4 and Nkx-2.5, 0.2 g of cDNA were used for real-time
RT-PCR performed with a Lightcycler system (Roche Diagnos-
tics) and with the SYBR Green fast start kit (Lightcycler Fast-
Start DNA MasterPLUS SYBR Green I). Primers used in real-
time RT-PCR were as follows: GATA-4 forward 5-TGGCCT-
GTCATCTCACTACG-3 and reverse 5-TAGCCTTGTGG-
GGAGAGCTT-3; Nkx-2.5 forward 5-CAAGTGTGCGTCT-
GCCTTT-3 and reverse 5-GCGCACAGCTCTTTCTTTTC-
3; VEGF forward 5-AGAAGGAGGAGGGCAGAATC-3
and reverse 5-ACACAGGATGGCTTGAAGATG-3; KDR
forward 5-CTGCAAATTTGGAAACCTGTC-3 and reverse
5-GAGCTCTGGCTACTGGTGATG-3; HGF forward 5-
ATTTGGCCATGAATTTGACCT-3 and reverse 5-ACTCC-
AGGGCTGACATTTGAT-3; GAPDH forward 5-CAGCCT-
CAAGATCATCAGCA-3 and reverse 5-TGTGGTCATGA-
GTCCTTCCA-3. The reaction mixture (20 l) contained 4 l
of Master SYBR Green I mix (TaqDNA polymerase, buffer,
deoxynucleoside trisphosphate mix, MgCl2, and SYBR Green I
dye) and 0.5 M concentrations of each primer to which 2 l of
cDNA was added. Data were normalized using GAPDH as an
index of cDNA content after reverse transcription. Amplifica-
tion included initial denaturation at 95 °C for 10 min, 45 cycles
of denaturation at 95 °C for 10 s, annealing at 55–65 °C for
6–10 s, and extension at 72 °C for 10 s, performed at a temper-
ature transition rate of 20 °C/s. Fluorescence was measured at
the end of each extension step. Specificity of the product was
determined by a melting curve analysis, conducted after com-
pletion of the cycling process with the aid of a temperature
ramp (from 55–95 °C at 0.1 °C/s) and continuous fluorescence
monitoring, confirmed by gel electrophoresis. Samples were
run in duplicate, and the average threshold cycle (Ct) value was
used for calculations. Relative quantification of mRNA expres-
sion was calculated with the comparative Ct method using the
“Delta-delta method” for comparing relative expression results
between treatments in real time PCR (21).
MyoD mRNA was determined by conventional RT-PCR
usingAmpliTaq under the following conditions; hot start for 10
min at 95 °C, 35 cycles of denaturation at 94 °C for 30 s, anneal-
ing at 56 °C for 30 s, extension at 72 °C for 30 s. Primers were:
forward 5-CGACGGCATGATGGACTAC-3 and reverse
5-AGGCAGTCTAGGCTCGACAC-3.
Isolation of Stem Cell Nuclei and Nuclear Run-off Transcrip-
tionAssay—Isolation of nuclei and assessment of nuclear purity
were performed as detailed elsewhere (20, 22). Only freshly iso-
lated nuclei were used in each experiment. Nuclear run-off
experiments were carried out as previously described (20).
Briefly, nuclear RNA was isolated by using guanidine thiocya-
nate and acid phenol extraction followed by purification on
RNAMATRIXTM. Equal counts of 32P-labeled RNA (about
5106 cpm) were then subjected to a solution hybridization
RNase protection assay and were hybridized for 12 h at 55 °C in
the presence of unlabeled antisense GATA-4, Nkx-2.5, HGF,
and GAPDH mRNA. To generate these cRNA probes, cDNA
fragments of human GATA-4 (237 bp), Nkx-2.5 (245 bp), HGF
(177 bp), or GAPDH (574 bp) genes were inserted into a pCRII-
TOPO vector. Transcription of plasmids linearized with
BamHI generated antisense strands of Nkx-2.5 and GAPDH
mRNA, whereas transcription of plasmids linearized with XbaI
produced an antisense strand of GATA-4 and HGF mRNA.
Samples were then incubated with a combination of RNase A
and T1 and exposed to proteinase K. The protected fragments
were recovered after phenol chloroform extraction and electro-
phoretically separated in a polyacrylamide non-denaturing gel.
Autoradiographic exposure was for 48 h.
Assay for Angiogenic and Growth Factors—To investigate
whether cell exposure to HBR may affect the production of
angiogenic, antiapoptotic, and mitogenic factors, hMSCs were
cultured for 14 days in the absence or presence of 2mg/mlHBR.
Then the levels of VEGF and HGF were measured in condi-
tioned medium at defined time intervals by enzyme immuno-
assay (Quantikine humanVEGF andHGF immunoassays, R&D
Systems, Inc.).
Immunostaining—Immunofluorescence analyses were per-
formed as previously described (22). Briefly, cells were washed
with PBS and fixed with 4% formaldehyde at room temperature
for 1 h. After fixation, cells were washed three times with PBS
and permeabilized with 0.2% Triton X-100 at room tempera-
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ture for 15 min. Aspecific antibody binding sites were blocked
by incubating with 1% bovine serum albumin for 1 h at 37 °C.
Then cells were labeled for 1 h at 37 °C in the presence of
mouse monoclonal antibodies directed against MHC
(MF20), -sarcomeric actinin, Cx43, and vWF. Excess pri-
mary antibody was removed by 3 washes with PBS, and the
cells were stained at 37 °C for 1 h with fluorescein-conju-
gated goat IgG. Microscopy was performed with a Bio-Rad
Microradians confocal microscope.
Myocardial Infarction, Stem Cell Implantation, and Func-
tional Evaluation of Myocardial Performance—Protocols were
approved by an institutional review board. Myocardial infarc-
tion was produced in male Wistar rats at 2 months of age,
according to previously described protocols (23). Briefly, under
ether anesthesia, the thoraxwas opened through a thoracotomy
performed at the fourth left intercostal space, the heart was
rapidly exposed and the left anterior descending coronary
artery was ligated with 6-0 mononylon thread during continu-
ous subcutaneous electrocardiographic monitoring for ST
changes and arrhythmias. After left anterior descending coro-
nary artery occlusion, 1 106 culture-expanded hMSCs resus-
pended in 100 l of sterile saline solution (PBS) were injected
into the viablemyocardiumbordering the infarct using an insu-
lin syringewith a 30-gauge needle. The ischemic zonewas iden-
tified by the pale color of the myocardium. Infarcted rats that
were injected with 100 l of PBS, and sham-operated rats in
which left anterior descending coronary artery was not
occluded were used as controls. Transthoracic echocardio-
graphy was performed before thoracotomy and 28 days there-
after in sedated rats with an Esaote Megas equipped with a
7.5-MHz linear transducer. Short and long axis two-dimen-
sional views and M-mode at the level of infarction were ana-
lyzed in real-time and recorded on a magnetooptic disk for
off-line analysis. Anterior and posterior end-diastolic and end-
systolic wall thicknesses and left ventricular (LV) internal
dimensions were measured, as recommended by the American
Society of Echocardiography (24, 25). Systolic ventricular func-
tion and global contractility were quantified such as fractional
shortening (%) and ejection fraction (%). Fractional shortening
was calculated from the composite LV internal, diastolic and
LV internal, systolic dimensions from M-mode short-axis
views. LV ejection fraction and cardiac output were calculated
from a long-axis view.
Tissue Immunohistochemistry—Hearts were arrested in dias-
tole and fixed as described (26) and then cut into 5-msections;
the sections were used for immunohistochemical studies to
localize the human transplanted cells using the antibodies
against human mitochondria protein (27, 28). Cardiac lineage-
committed cells were identified by antibodies directed against
Cx43 and TnI. Endothelial lineage-committed cells were iden-
tified with an antibody directed against human vWF. Briefly,
the sections were dewaxed with xylene and rehydrated through
decreasing concentrations of ethanol. Endogenous peroxidase
activity was blocked by a 10-min incubation at room tempera-
ture with absolute methanol containing 3% H2O2. Antigen
retrieval was performed by immersion of the slides in a jar con-
taining citrate buffer (pH 6) and treatment at 120 °C, 1 atm, for
21min. After cooling and washing, the samples were incubated
overnight at 4 °C in amoist chamberwith the antibodies against
human mitochondria (1:100, Chemicon), vWF (1:50, Dako
Cytomation), Cx43 (1:200, Zymed Laboratories Inc.), and TnI
(1:400, Covance). Monoclonal antibody tissue labeling was
revealed by using a non-biotin polymeric system (Super Sensi-
tive Polymer HRP IHC Detection Systems; Biogenex, San
Ramon, CA). After washing, the slides were incubated for 20
min at room temperaturewith Super Enhancer reagent, washed
in PBS, and then incubated for 30 min at room temperature
with super sensitive horseradish peroxidase polymeric com-
plexes. Then the slides were incubated with diaminobenzidine
tetrahydrochloride peroxidase substrate solutions, rinsed in
distilled water, and then counterstained with hematoxyline.
The samples were dehydrated, mounted, and viewed in a light
microscope using the ImageProPlus. To demonstrate that the
same transplanted human cells were also positive for Cx43 or
TnI, we performed a double immunofluorescent staining. For-
malin-fixed, paraffin-embedded tissue sections were dewaxed
in xylene and then rehydrated in a graded series of ethanol. To
recover tissue antigenicity, the slides were immersed in citrate
buffer (pH 6) and treated at 120 °C, 1 atm, for 21 min. After
cooling and washing, the samples were incubated in a blocking
solution containing 2% rabbit serumand1%bovine serumalbu-
min in PBS for 30 min at room temperature to reduce the
unspecific binding. Afterward, the tissue samples were first
incubated with anti-humanmitochondria at 4 °C overnight in a
moist chamber,washed, and then labeledwith polyclonal rabbit
anti-mouse-fluorescein isothiocyanate (1:100, Dako Cytoma-
tion) for 45min at 37 °C in the dark; then the slideswerewashed
several times to remove any unbound secondary antibody,
treated with the blocking solution, and incubated at 4 °C over-
night with anti Cx43 (1:200) or anti TnI (1:400) monoclonal
antibodies. After overnight incubation, the slides were washed
and incubated for 45 min at 37 °C in the dark with goat anti-
mouse (TRITC)-conjugated antibody (1:100, ICN Cappel).
After washing, the slides were mounted, and the nuclei were
counterstained with 4,6-diamidino-2-phenylindole using the
kit “Pro long antifade reagent” (Molecular Probes, Milano,
Italy). Negative controls were performed omitting the primary
antibodies.
Data Analysis—The statistical analysis of the data were
performed by using a one-way analysis of variance and the
Bonferroni test assuming a p value less than 0.05 as the limit
of significance.
RESULTS
Flow cytometry revealed that BMhMSCs, DPhMSCs, and
FMhMSCswere positively stained with SH2 (supplemental Fig.
1), which identifies an epitope of endoglin (CD105), the trans-
forming growth factor- receptor III present on endothelial
cells, erythroblasts, monocytes, and connective tissue stromal
cells, facilitating the enrichment of stromal progenitors from
bone marrow (29). Like BMhMSCs, DPhMSCs and FMhMSCs
were recognized by the SH3 and SH4 antibodies (supplemental
Fig. 1), which identify epitopes on culture-expanded stromal
cells and bind CD73, a molecule involved in B-cell activation
(30). Each group of hMSCs was positive for CD29 (supplemen-
tal Fig. 1), the -subunit of an integrin family behaving as the
Hyaluronan, Glycoconjugates, and Cardiac Repair
14246 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 19•MAY 11, 2007
 at CNR ISTITUTO
 BIO
FISICA - TRIAL SUBSCRIPTIO
N, on April 18, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
major receptor for extracellular matrix molecules. Cells also
expressed CD166, an hMSC marker not found in hematopoi-
etic precursors (31), and were uniformly positive for the CD44
hyaluronate receptor (supplemental Fig. 1). Conversely, anti-
gen profiles were negative for the hematopoieticmarkers CD14
and CD34 and the leukocyte common antigen CD45 (supple-
mental Fig. 1). These observations and the comparative analysis
of surface antigen expression (supplemental Table 1) indicate
that both DPhMSCs and FMhMSCs can be regarded as alter-
native sources for hMSC-like elements.
In each hMSC population HBR dose-dependently increased
the expression ofGATA-4 andNkx-2.5mRNA, encoding a zinc
finger and a homeodomain essential for cardiogenesis in differ-
ent animal species (32, 33), including humans (34). Real-time
RT-PCR revealed that the HBR effect peaked at 1.5 mg/ml in
both BMhMSCs and DPhMSCs, reaching a maximum at 2.0
mg/ml in FMhMSCs (Fig. 1, A and B). In BMhMSCs exposed
for 7 days to HBR, both GATA-4 and Nkx-2.5 mRNA were
subjected to more than a 20-fold increase, as compared with
untreated cells. The transcriptional response to HBR was even
more remarkable in DPhMSCs and FMhMSCs (Fig. 1). HBR did
not affectMyoDmRNA, a transcript involved in skeletalmyogen-
esis (Fig. 1C). BothMHCand-sarcomeric actininwereexpressed
in a limited number (1–5%) of untreated hMSCs (Fig. 1). Inter-
estingly, in each hMSC population
HBR remarkably increased the yield
of cells expressing each cardiac
marker protein (Fig. 1). Most of
HBR-treated hMSCs connected
with neighboring positively stained
cells. Cardiac lineage commitment
was further inferred from the obser-
vation that HBR exposure was asso-
ciated with a sarcomeric-like orga-
nization of -sarcomeric actinin
staining (Fig. 1) and resulted in
Cx43 expression along regions of
intimate cell-to-cell contact (Fig. 1).
Neither sarcomeric-like features
nor Cx43 expression was detected
in untreated cells (not shown). Flow
cytometry analysis confirmed that
treatment with HBR consistently
increased the percentage of -sar-
comeric actinin-positive cells. After
14 days of exposure to 2 mg/ml
HBR, 36.80  1.50% of FMhMSCs
expressed -sarcomeric actinin,
whereas the percentage of positive
cells was 30.20  0.85% in DPhM-
SCs or 16.12  0.80% in BMhM-
SCs (mean  S.E.; n  4). Under
the same experimental conditions,
the percentages of Cx43-express-
ing cells in BMhMSCs, DPhMSCs,
and FMhMSCs were 13.20  1.40,
22.8  1.65, and 33.0  2.4%
(mean  S.E.; n  4), respectively.
Real-time RT-PCR provided evidence that exposure to HBR
dose-dependently increased the expression of VEGF-A mRNA
(Fig. 2A) and that of the KDR gene (Fig. 2B), encoding a major
VEGF receptor. HBR also remarkably enhanced the expression
of HGF mRNA (Fig. 2C). These genes have been shown to play
a pivotal role in both endothelial tissue formation (vasculogen-
esis) and sprouting of new blood vessels from pre-existing ves-
sels (angiogenesis) (35–38). TheHBR effect on gene expression
was more pronounced in FMhMSCs than in BMhMSCs or
DPhMSCs.
Each cell population secreted consistent amounts of angio-
genic and antiapoptotic factors, including VEGF and HGF.
Similar to mRNA expression, the relative protein levels
assessed during a 14-day period of culture were higher in
FMhMSCs (Fig. 2, D and E) than in BMhMSCs or DPhMSCs
(data not shown). In FMhMSCs, the concentration of each
growth factor was significantly higher in the supernatant of
HBR-treated cells than in the culture medium from untreated
controls (Fig. 2, D and E). Time-course analyses revealed that
the stimulatory effect was evident after 3 days and progressively
increased persisting throughout an overall period of 14 days
(Fig. 2, D and E).
Undifferentiated hMSCs showed no appreciable staining
for vWF, a marker for endothelial specification, but after 14
FIGURE1.HBRprimes theexpressionof cardiac lineage-promoting transcriptswithoutaffectingskeletal
myogenesis. GATA-4 (A) and Nkx-2.5 (B) mRNA expression were measured by real-time RT-PCR. Cells were
treated for 7 days in the absence or presence of HBR. The abundance of each mRNA in untreated cells was
defined as 1, and the amounts of GATA-4 or Nkx-2.5mRNA fromHBR-treated cells were plotted relative to that
value (mean S.E.; n 6). *, significantly different from untreated cells (controls). MyoDmRNA expression (C)
was assessed by conventional RT-PCR. Cells were treated for 7 days in the absence () or presence () of 1.5
mg/ml HBR (BMhMSCs (BM) and DPhMSCs (DM)) or 2 mg/ml HBR (FMhMSCs (FM)). Human skeletal muscle
mRNA (c) was used as a positive control (ethidium bromide-stained agarose gels, representative of four sepa-
rate experiments). For immunofluorescence analyses cells were cultured for 14 days in the absence (HBR) or
presence (HBR) of 1.5mg/ml HBR andwere stainedwithmonoclonal antibodies directed against sarcomeric
MHC or -sarcomeric actinin (-actinin). Scale bars are 100 m. Sarcomeric-like organization of -sarcomeric
actinin staining (-actinin), and Cx43 expression were only evident in each cell population that had been
cultured for 14 days in the presence of 1.5 mg/ml HBR. Scale bars are 20 m. Nuclei are labeled by 4,6-
diamidino-2-phenylindole (blue).
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days of HBR treatment vWF expression was clearly evident,
and Weibel-Palade bodies were also visible (Fig. 2F). The
percentage of vWF-expressing cells was higher in FMhMSCs
as compared with DPhMSCs or BMhMSCs (Fig. 2F). Similar
percentages of both -sarcomeric actinin- and vWF-positive
cells were observed when BMhMSCs, DPhMSCs, or FMhMSCs
were treated for 14 days with HBR and then cultured in the
absence of HBR for additional 14 days (supplemental Fig. 2).
We investigated whether CD44, a hyaluronan binding
molecule highlyexpressed inBMhMSCsandDPhMSCsaswell as
FMhMSCs, may be involved in the differentiating response to
HBR. Cell culture in the presence of a CD44-specific blocking
monoclonal antibody (A3D8) resulted in the complete suppres-
sion of the ability of HBR to commit FMhMSCs into both car-
diac and endothelial lineages (supplemental Fig. 3). Results
from competition experiments
indicated that the cardiogenic
action of HBR was also dose-
dependently counteracted by HA
(supplemental Fig. 3). To further
dissect the hMSC response to HBR,
nuclear run-off experiments were
designed to assess whether HBR
may have affected the rate of tran-
scription of cardiogenic/angiogenic
genes and whether, in the affirma-
tive, it may have acted as a unit or
after hydrolysis of hyaluronan-
grafted moieties. Supplemental Fig.
4 shows that nuclei isolated from
FMhMSCs that had been cultured
for 7 dayswithHBR exhibited a con-
sistent increase in the transcription
rate of GATA-4, Nkx-2.5, and HGF
genes as compared with nuclei iso-
lated from untreated cells. In sepa-
rate experiments nuclei were iso-
lated from untreated cells and
subsequently incubated with HBR
or exposed to HA, BU, or RA
administered alone or in combina-
tion. Although nuclear exposure to
HBR or HA failed to trigger a tran-
scriptional response, the incubation
with BU or RA enhanced GATA-4,
Nkx-2.5, and HGF gene transcrip-
tion (supplemental Fig. 4). The tran-
scription rate of these geneswas fur-
ther enhanced when nuclei were
exposed to a combination of BU and
RA (supplemental Fig. 4).
We next investigated whether
hMSC treatment with HBR in vitro
before cell delivery in vivomay rep-
resent a novel strategy for the rescue
of damaged hearts. To this end
FMhMSCs, which exhibited the
most pronounced commitment to
cardiovascular lineages and enhanced release of trophic factors
in response to HBR, were cultured for 14 days in the absence or
presence of thismixed ester and subsequently transplanted into
infarcted rat hearts. Four weeks aftermyocardial infarction, the
non-transplanted group showed indices of cardiac failure (Fig.
3). In marked contrast, echocardiographic analysis of infarcted
rats receiving FMhMSCs non-exposed to HBR revealed a
recovery to essentially normal indices of cardiac function (Fig.
3). A similar normalization was observed after transplantation
of HBR-treated cells (Fig. 3). Injection of pretreated cells
resulted in significantly higher values of left ventricle to body
weight ratio and diastolic thickness as compared with
untreated FMhMSCs (Fig. 3). No significant recovery of cardiac
function was observed 1 or 2 weeks after the injection of
untreated or HBR-exposed FMhMSCs (not shown).
FIGURE 2. HBR induces a gene program of angiogenesis and enhances the secretion of angiogenic,
antiapoptotic, and mitogenic factors, leading to endothelial lineage commitment. VEGF-A (A), KDR (B),
and HGF (C) gene expression were assessed by real-time RT-PCR. Cells were cultured for 7 days in the absence
or presence of HBR. The abundance of each mRNA in untreated cells was defined as 1, and the amounts of
VEGF-A, KDR, or HGF mRNA from HBR-treated cells were plotted relative to that value (mean  S.E.; n  6).
*, significantly different from untreated cells (controls).D and E, time-course analysis of VEGF andHGF, respec-
tively, releasedbyFMhMSCs cultured in the absence (white bar) or presence (gray bar) of 2mg/mlHBR (mean
S.E.; n 6). *, significantly different from untreated cells. F, immunofluorescence analysis of vWF expression
was investigated in BMhMSCs (BM), DPhMSCs (DP), and FMhMSCs (FM) cultured for 14 days in the presence of
1.5 mg/ml HBR (scale bars are 20m). No appreciable staining for vWF was observed in cells cultured without
HBR. The figure reports the percentage (mean  S.E.; n  4) of HBR-treated hMSCs exhibiting the typical
granular patterning of vWF staining. For comparison, the effect of VEGF (50 ng/ml for 14 days) on vWF expres-
sion is also reported. N.D., not determined.
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Gross pathologic examination of ischemic myocardium
after nitro blue tetrazolium staining revealed that FMhMSC
transplantation substantially decreased the percentage of
left ventricle occupied by fibrosis. Further remarkable
reduction in scar tissue formation was observed after injec-
tion of HBR-treated FMhMSCs. Interestingly, in this group
the unstained tissue (possibly reflecting infarct scarring) was
only confined to a limited area in the subendocardial zone,
which also exhibited regions of viable tissue. Picro-Mallory
trichrome staining and quantitative analyses showed that the
infarct area was significantly lower in animals receiving
HBR-treated FMhMSCs than in the group transplanted with
untreated cells (Fig. 4).
To assess whether injected FMhMSCsmay differentiate into
endothelial cells, sections from infarct regions of each experi-
mental groupwere incubated in the presence of human-specific
anti-vWF antibody. No staining was detected in samples from
placebo-treated animals (Fig. 5). On the contrary, vWF-positive
cells were observed in cardiac samples from infarcted animals
injected with both untreated or HBR-exposed cells (Fig. 5).
However, the number of vWF-expressing FMhMSCs was
remarkably higher in sections from hearts receiving HBR-pre-
treated cells than in samples with untreated FMhMSCs (Fig. 5).
Moreover, a consistent number of capillaries containing vWF-
positive FMhMSCs was observed in samples harvested from
hearts injected withHBR-pretreated cells, whereas no evidence
for organization of vWF-stained FMhMSCs into capillary
structures was found in sections from hearts transplanted with
untreated cells (Fig. 5).
Fig. 5 also shows that the density of capillary vessels lacking
cells positively stained with anti-human vWF was significantly
increased at the infarct border zone of animals injected with
untreated FMhMSCs as compared with infarcted tissue receiv-
ing saline as a placebo. The density of capillaries negative for
anti-human vWF staining was further augmented after trans-
plantation of HBR-pretreated FMhMSCs (Fig. 5).
Immunofluorescence analysis also provided evidence that
engrafted HBR-pretreated cells concomitantly expressed Cx43
or cardiac TnI with a human-specific anti-mitochondria anti-
body (Fig. 6) and that the number of positive FMhMSCs
exceeded that observed in hearts transplanted with untreated
cells. However, this low yield of cardiacmarker-expressing cells
appeared to lack complete myogenic differentiation with
mature sarcomeric organization.
FIGURE 3. Assessment of cardiac function in infarcted rat hearts trans-
plantedwith FMhMSCs cultured in theabsenceorpresenceofHBR. Tran-
sthoracic echocardiography was performed in normal sham-operated rats
without left anterior descending coronary artery occlusion (A) and 28 days
after myocardial infarction in animals receiving saline as a placebo (B) or
FMhMSCspreviously cultured for 14days in the absence (C) or presence (D) of
1.5 mg/ml HBR. *, significantly different from A; §, significantly different from
B; # in D, posterior wall thickness is significantly different from anterior wall
thickness; ‡, significantly different fromC. Data in each group are themean
S.E. from six individual animals (one-way analysis of variance and Bonferroni
test, assuming a p value less than 0.05 as the limit of significance). bpm, beats
per minute.
FIGURE 4. Impact of FMhMSC injection on infarct size. Upper panel, repre-
sentative example of scar formation 4 weeks after myocardial infarction in
rats treatedwith saline as aplacebo (A) or FMhMSCspreviously cultured for 14
days in the absence (B) or presence (C) of 1.5mg/ml HBR. Macroscopic infarct
size was assessed in each group by nitro blue tetrazolium staining. 3-mm-
thick transverse slices cut through the short axis of both ventricles atmidsep-
tal level were processed for light microscopy, stained with picro-Mallory
trichrome (upper panel), and digitalized through a video camera connected
with themicroscope. Lower panel, infarct sizes (blue-stainedareas)werequan-
tified by using image Pro Plus Version 8 (Media Cybernetics). *, significantly
different from A; §, significantly different from B. Data in each group are the
mean  S.E. from six individual animals (one-way analysis of variance and
Bonferroni test, assuming a p value less than 0.05 as the limit of significance).
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DISCUSSION
During myocardial infarction, cardiomyocyte loss is associ-
ated with hibernation of underperfused heart cells. Pluripotent
hMSCs differentiate into a variety of cells, including cardiom-
yocytes and endothelial cells and may hold promises for both
replacing the lost heart cells (cardiomyogenesis) and restoring
perfusion of the hibernating cells (vasculogenesis or angiogen-
esis). It is also becoming increasingly evident that hMSCs may
secrete large amounts of angiogenic, antiapoptotic, and mito-
genic factors and that the improvement of cardiac function and
reduction in scar formation observed in animal models of myo-
cardial infarction after hMSC transplantationmay bemediated
by the supply of these trophic factors (12–14). In this regard
bone marrow-derived mesenchymal stem cells overexpressing
Akt have been shown to inhibit ventricular remodeling and
restore cardiac functionmainly through paracrinemechanisms
involving an increase in the expression of VEGF, fibroblast
growth factor-2, and HGF genes and enhanced secretion of
their related products (39, 40). Consonant with these observa-
tions, monolayered adipose tissue-derived mesenchymal stem
cells repaired scarred myocardium in infarcted rat hearts, act-
ing as trophic mediators for paracrine angiogenic pathways
(41).
Despite these attractive properties of hMSCs, their potential
as a cell therapeutic for cardiac repair is limited by age and
disease states affecting the collection of sufficient healthy autol-
ogous bone marrow-derived cells for transplantation. A poten-
tial use of stem cells in cardiac repair is also hampered by the
low yield of cardiac lineage commitment in both adult and ES
cells. Hence, the identification of pluripotent cells transplant-
able in an allogenic setting and the development of differenti-
ating molecules enhancing both stem cell commitment to car-
diovascular lineages and secretion of trophic factors may prove
rewarding in sight of cardiac cell therapy.
Here we show that DPhMSCs and FMhMSCs, like BMhMSCs,
exhibit a low yield commitment to a myocardial-like lineage in
vitro. HBR increased the expression of cardiac lineage-promot-
ing genes without affecting MyoD mRNA. This observation
seems to exclude a generalized activation of repressed genes.
The ability of HBR to enhance cardiogenesis in vitro is also
inferred by the observation that the mixed ester enhanced the
amount of cells expressingMHC and -sarcomeric actinin and
by the finding that Cx43-positive cells only developed from
HBR-treated hMSCs. Interestingly, exposure to HBR remark-
ably enhanced the transcription of genes tightly involved in
FIGURE 5. Capillary density and development of transplanted FMhMSCs
into endothelial cells at the infarcted region. Sectionswere obtained from
border zone 4 weeks after myocardial infarction. A, expression of vWF was
assessed by immunohistochemistry with an anti-human vWF antibody.
Although no stainingwas detected in samples from placebo-treated animals
(P), a consistent number of vWF-positive cells was observed in the tissue har-
vested from animals injected with FMhMSCs previously cultured for 14 days
in the absence (FM) or presence (FM*) of 1.5 mg/ml HBR. Organization into
erythrocyte-containing capillary-like structures (lower right) was observed in
samples from hearts transplanted with HBR-treated cells. Light microscopy,
20 (original magnification). Scale bars are 20m. B, quantitative analysis of
vWF-expressing cells. The number of FMhMSCs positively stained with anti-
human vWF antibody and the density of capillary vessels containing vWF-
positive FMhMSCswere counted in randomly selected five-high-power fields
of each section and averaged. *, significantly different from FM. C, density of
capillary vessels lacking positive staining with anti-human vWF antibody at
the infarct border zone. *, significantly different from placebo-treated ani-
mals; §, significantlydifferent fromFM.Data are themeanS.E. fromsections
of six individual animals.
FIGURE6.Developmentof transplantedFMhMSCs intoCx43- andcardiac
troponin I-positive cells. A, 4 weeks after myocardial infarction, Cx43 or TnI
expression were investigated in samples from rats injected with FMhMSCs
previously cultured for 14 days in the absence (FM) or presence (FM*) of 1.5
mg/ml HBR. Sections were double-stained with human-specific anti-mito-
chondrial antibody (Mit, green fluorescence), and antibody was directed
against Cx43 or cardiac TnI (red fluorescence). Double-labeled cells are shown
inmerged (M) images. Nuclei were labeled by 4,6-diamidino-2-phenylindole
(DAPI,blue signal). Lightmicroscopy, 100 (originalmagnification). Scale bars
are 20 m. B, quantitative analysis of the number of Cx43- or TnI-expressing
FMhMSCs. Positive cells were counted in randomly selected five-high-power
fields of each sectionandaveraged. *, significantly different fromFM.Data are
the mean S.E. from sections of six individual animals.
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vasculogenesis and angiogenesis and led to the development
of vWF-expressing endothelial cells. The attainment of car-
diomyocyte- and endothelial-related features was a long-
lasting differentiating response, as suggested by the pro-
longed persistence of markers for both lineages in high
percentages of hMSCs even after HBR withdrawal. The pres-
ent finding that FMhMSCs secreted large amounts of VEGF
and HGF and that HBR consistently increased the secretion
of each trophic mediator is worthy of consideration. In fact,
besidesVEGF,HGFhas not only angiogenic but also cardiopro-
tective effects, including antiapoptotic, mitogenic, and antifi-
brotic activities (42, 43). HGF gene transfer into the myocar-
dium improved myocardial function and geometry (44), in
particular because of antifibrotic effects through inhibition of
transforming growth factor- expression. Therefore, taking the
present findings together, HBR appears to encompass both dif-
ferentiating features for hMSC commitment to cardiovascular
lineages and the potential to afford growth factor-mediated
paracrine regulation.
Akin to these considerations and taking into account that in
vitro responses to HBR were considerably more accentuated in
FMhMSCs than in BMhMSCs or DPhMSCs, we designed sep-
arate in vivo experiments to assess whether FMhMSCs may be
used to repair infarcted rat hearts and whether their rescuing
potential may be enhanced by cell pretreatment with HBR.
Notably, untreated FMhMSCs led to normalization of left ven-
tricular function and remarkable reduction in infarct size and
scar tissue. The observation that these cells exhibited a very low
yield of myocardial commitment and failed to differentiate into
endothelial cells spontaneously in vitro prompt the hypothesis
that FMhMSCs may have acted as trophic mediators to rescue
the infarcted myocardium. Such a hypothesis is supported by
the ability of FMhMSCs to spontaneously secrete large
amounts of angiogenic, antiapoptotic, and mitogenic factors in
vitro. The possibility that these factors may have protected the
infarcted myocardium in a paracrine fashion is inferred by the
finding that FMhMSC transplantation was followed by a signif-
icant increase in the density of capillary vessels lacking positive
staining against human vWF, likely reflecting an angiogenic
response of the recipient tissue to the injected FMhMSCs.
Although cardiac performance was similarly recovered after
injection of untreated or HBR-exposed cells, the transplanta-
tion of HBR-pretreated FMhMSCs led to increased left ventri-
cle to bodyweight ratio and diastolic thickness aswell as further
reduction in infarct size as compared with untreated cells. The
finding that in vitro exposure of FMhMSCs to HBR enhanced
the secretion of VEGF and HGF suggests that the beneficial
effects exerted in vivo by HBR-preconditioned cells may be due
at least in part to enhanced cardioprotection through growth
factor-mediated paracrine patterning. In this regard the injec-
tion of HBR-treated cells was followed by a significant increase
in density of capillaries negative for anti-human vWF com-
pared with the capillary density observed in the tissue receiving
untreated cells. Enhanced in vivo release of VEGF and HGF by
HBR-pretreated FMhMSCs may have contributed both to the
observed angiogenic response and the reduction of infarct size
and scar formation through antiapoptic and antifibrotic
activities.
The current data also show that in the hearts injected with
HBR-exposed cells, the number of FMhMSCs positively
stained with a human-specific anti-vWF antibody remarkably
exceeded the number of vWF-positive cells detected in samples
from the untreated group. It is worthy to note that a consistent
organization of vWF-positive FMhMSCs into capillary struc-
tures was only observed in hearts transplanted with HBR-
treated cells. Hence, the endothelial lineage commitment
primed by HBR in vitro was retained within the transplanted
cells in the infarctedmyocardium, suggesting that HBR-treated
cells may also contribute to neovascularization and heart res-
cue through their ability to generate capillary-like structures.
The relative contribution of growth factor-mediated paracrine
mechanisms and differentiation into vascular lineages by HBR-
treated FMhMSCs within the infarcted heart remains to be
established and is the subject for further investigations. Some of
the transplanted cells that had been pretreated with HBR
also exhibited a colocalization of Cx43 and cardiac TnI with
a human mitochondrial protein. Nevertheless, these cells
lacked mature sarcomeric organization, and their role in
restoring the cardiac performance within the infarcted tissue
remains questionable.
The molecular dissection of mechanisms underlying HBR-
mediated responses in vitro and in vivo remains to be fully elu-
cidated. The finding thatCD44was expressed inmore than 95%
of BMhMSCs, DPhMSCs, and FMhMSCs and that cell expo-
sure to a CD44-specific blocking monoclonal antibody abro-
gated HBR-mediated cardiac and endothelial commitment
indicate that engagement of the hyaluronan CD44 receptor
may represent a major initial step in the signaling cascade trig-
gered by the mixed ester. The possibility that HBR uses a hya-
luronan-related uptake system for cell entry is further sug-
gested by results of competition experiments showing that HA
dose-dependently decreased the yield of cells committed to
both cardiac and endothelial lineages in the presence of the
glycoconjugate. Nuclear run-off experiments indicate that the
action of HBR was mediated at the transcriptional level. How-
ever, the transcription rate of GATA-4, Nkx-2.5, and HGF was
unaffected after a direct exposure of nuclei isolated from undif-
ferentiated cells to HBR. On the contrary, the transcription of
these cardiogenic/angiogenic genes was increased by nuclear
exposure toBUorRAandwas additively enhanced by amixture
of the two. These results prompt the hypothesis that, at least at
nuclear level, HBR may have acted after the hydrolysis of its
grafted moieties.
In conclusion, we show the possibility of using a novel glyco-
conjugate to enhance both vascular differentiation and the
secretion of angiogenic, antiapoptotic, and mitogenic factors
from FMhMSCs. These cells do not induce allogeneic or xeno-
geneic lymphocyte proliferation and actively suppress lympho-
cyte responsiveness (18). Moreover, FMhMSC transplantation
in neonatal swine and rats resulted in human microchimerism
in various organs and tissues (18), suggesting that FMhMSCs
may be administered as allogeneic grafts without the need of
bone marrow harvests on recipient subjects. The current find-
ings may contribute to further development in cell therapy for
heart failure.
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